Roche: FDA approves lung cancer therapy

(CercleFinance.com) - Roche announces that the US FDA has approved its Alecensa (alectinib) as the first adjuvant therapy after tumor resection for patients with early-stage ALK-positive non-small cell lung cancer (NSCLC).


This approval is based on the ALINA phase III study showing that Alecensa reduces the risk of recurrence or death by an unprecedented 76% in people with ALK-positive NSCLC resected at an early stage.

It helps address an urgent unmet need, as around half of all people with early-stage NSCLC experience disease recurrence after surgery, despite adjuvant chemotherapy, the Swiss healthcare group says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.